Zobrazeno 241 - 250
of 672
pro vyhledávání: '"Emanuele Zucca"'
Autor:
Patrice Herait, Keyvan Rezai, Anastasios Stathis, Florence Broussais, Sandy Amorim, Catherine Thieblemont, Xavier Leleu, Antonio Palumbo, Lionel Karlin, François Lokiec, Sunil Iyengar, Gilles Salles, Mary Gleeson, Emanuele Zucca, Valeria Magarotto, Franck Morschhauser, David Cunningham, Thierry Facon, Carmen Kahatt
Publikováno v:
Lancet Haematology
Lancet Haematology, Elsevier, 2016, 3 (4), pp.e196-e204. ⟨10.1016/S2352-3026(16)00021-1⟩
Lancet Haematology, Elsevier, 2016, 3 (4), pp.e196-e204. ⟨10.1016/S2352-3026(16)00021-1⟩
International audience; BACKGROUND: The first-in-class small molecule inhibitor OTX015 (MK-8628) specifically binds to bromodomain motifs BRD2, BRD3, and BRD4 of bromodomain and extraterminal (BET) proteins, inhibiting them from binding to acetylated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afd6aa4b2ee6c9a1288e48160e38ec67
https://hal.archives-ouvertes.fr/hal-01791283
https://hal.archives-ouvertes.fr/hal-01791283
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(6)
Autor:
Michele Reni, Mascha Binder, Angela Ferrari, Roberta Rudà, Ulrich Keller, Tobias Pukrop, Bernd Hertenstein, Georg Hess, Gerald Illerhaus, Peter Johnson, Stephan Stilgenbauer, Claire Hemmaway, Elisabeth Schorb, Paul La Rosée, Francesco Pisani, Jens Panse, Achille Ambrosetti, Monica Balzarotti, Franco Cavalli, Jürgen Finke, Kate Cwynarski, Emanuele Zucca, Martina Deckert, Andrés José Maria Ferreri, Alexander Röth, Alberto Fabbri, Valter Torri, Alessandro Levis, Alessandra Tucci, Letterio S. Politi, Elisa Jacobsen Pulczynski, Kim Linton, Stefan W. Krause, Christopher P. Fox, Maurilio Ponzoni, Hans J. Schmoll, Jette Sønderskov Gørløv
Publikováno v:
Ferreri, A J M, Cwynarski, K, Pulczynski, L E S J, Ponzoni, M, Deckert, M, Politi, L S, Torri, V, Fox, C P, Rosée, P L, Schorb, E, Ambrosetti, A, Roth, A, Hemmaway, C, Ferrari, A, Linton, K M, Rudà, R, Binder, M, Pukrop, T, Balzarotti, M, Fabbri, A, Johnson, P, Gørløv, J S, Hess, G, Panse, J, Pisani, F, Tucci, A, Stilgenbauer, S, Hertenstein, B, Keller, U, Krause, S W, Levis, A, Schmoll, H J, Cavalli, F, Finke, J, Reni, M, Zucca, E, Illerhaus, G & International Extranodal Lymphoma Study Group (IELSG) 2016, ' Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma : results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial ', Lancet Haematol, vol. 3, no. 5, pp. e217-27 . https://doi.org/10.1016/S2352-3026(16)00036-3
BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and effica
Autor:
Peter Johnson, Alberto Biggi, Emanuele Zucca, Ur Metser, Stephane Chauvie, Bogdan Małkowski, Sally F. Barrington, Luca Ceriani, Maurizio Martelli, Annibale Versari, Andrew Davies
The International Extranodal Lymphoma Study Group (IELSG)-37 is a prospective randomized trial assessing the role of consolidation mediastinal radiotherapy after immunochemotherapy to patients with newly diagnosed primary mediastinal large B-cell lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d81a384e1dc7f103fbfb70b27fb0ed
http://hdl.handle.net/11573/932495
http://hdl.handle.net/11573/932495
Autor:
Erika Lerch, Dominik Heim, Alessandra Cerutti, Luciano Wannesson, Urs Hess, Mario Bargetzi, Christoph Renner, Panagiotis Samaras, Emanuele Zucca, Anne Cairoli, Thomas Pabst
Publikováno v:
Leukemia & Lymphoma. 54:36-40
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) escalated is the preferred upfront Hodgkin lymphoma (HL) treatment in a number of countries. Upon failure, high-dose chemotherapy with autologous
Autor:
Annarita Conconi, Emanuele Zucca, Alden A. Moccia, Francesco Bertoni, Chiara Lobetti-Bodoni, Paola M.V. Rancoita, Anastasios Stathis, Franco Cavalli, Luca Mazzucchelli, Michele Ghielmini, Maddalena Motta, Carlotta Ponzio
Publikováno v:
British Journal of Haematology. 157:188-196
Histological transformation (HT) into diffuse large B-cell lymphoma (DLBCL) was documented in 37 of the 281 (13%; 95% CI, 9-18) follicular lymphoma (FL) patients treated at our institute from 1979 to 2007. HT occurred at a median of 2·75 years from
Autor:
Emanuele Zucca, Markus Joerger, Jan H.M. Schellens, Thomas Cerny, Andrés J.M. Ferreri, Alwin D. R. Huitema, Stephan Krähenbühl
Publikováno v:
British Journal of Clinical Pharmacology. 73:240-247
There is no consensus regarding optimal dosing of high dose methotrexate (HDMTX) in patients with primary CNS lymphoma. Our aim was to develop a convenient dosing algorithm to target AUC(MTX) in the range between 1000 and 1100 µmol l(-1) h.; A popul
Autor:
Michele Ghielmini, Auro Del Giglio, Christine Biaggi Rudolf, Thomas Pabst, Christian Taverna, Andreas Lohri, Ingmar A.F.M. Heijnen, Daniel A. Vorobiof, Giovanni Martinelli, Emanuele Zucca, Daniele Laszlo, Daniel Rauch, Walter Mingrone, Felicitas Hitz, Johann Raats, Lidija Cevreska, Anna Vanazzi, Stephanie Rondeau, Corinne Rusterholz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(5)
Purpose Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. Patients and Methods Two hundred seventy patients
Autor:
Gilles Salles, Michele Ghielmini, Michael Pfreundschuh, Christian Gisselbrecht, Isabelle Fleury, Catherine Thieblemont, M.H.J. van Oers, Sylvie Chevret, Michael Herold, B. Coiffier, Emanuele Zucca
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(3)
Background Addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy improves response rates and survival in patients with B-cell non-Hodgkin lymphoma (NHL). However, rituximab induces a transient B-cell depletion and a dose-dependent T
Autor:
Qian Shi, M. Ladetto, Eva Kimby, Gilles Salles, Catherine Sebban, Jesse G. Dixon, F. Morschhauser, Luc Mathieu Fornecker, Bruce A. Peterson, Robert Marcus, Kenneth A. Foon, A. Hagenbeeck, E. Gyan, Carla Casulo, Eva Hoster, Tina Nielsen, Christopher R. Flowers, Howard S. Hochster, Wolfgang Hiddemann, Mathias J. Rummel, Michael Herold, Fang-Shu Ou, Emanuele Zucca, Umberto Vitolo
Publikováno v:
Hematological Oncology. 35:225-226